LIFEARC
LIVE

Serial Number

79412583

Owner

LIFEARC

Attorney

David M. Abrahams

Filing Date

Apr 29, 2024

Add to watchlist:

No watchlists yet
View on USPTO

LIFEARC Trademark

Serial Number: 79412583 • Registration: 8226555

LIFEARC is a trademark filed by LIFEARC on April 29, 2024. The trademark is classified under Class 9 (Computers & Electronics), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 16 (Paper Goods), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

LIFEARC (3 trademarks)

7th Floor, Lynton House,

Entity Type: 99

Trademark Details

Filing Date

April 29, 2024

Registration Date

April 28, 2026

Published for Opposition

March 10, 2026

Goods & Services

Legal services; licensing of technology, namely, patent licensing; licensing and intellectual property services in relation to technology transfer services, namely, consulting in the field of intellectual property; advisory, consultancy and information services relating to all the aforesaid.

Scientific, medical and clinical research services; scientific research and scientific analysis in the field of biotechnology; scientific research and scientific analysis in the field of biochemistry; scientific research and scientific analysis in the field of biology; conducting clinical trials for others; data mining; data security consultancy services; data encryption services; database design and development; maintenance of computer software for databases; mathematical modelling services; scientific and technological services, namely, scientific research and analysis in the field of bioinformatics; drug discovery services; laboratory research in the field of medicine; computer programming and software design services; scientific research and development in the field of medical technology; research on the development and adaptation of health technology and health-related outcomes associated with implementation of health technology; clinical research services, namely, calibration, analysis and reporting of data in connection with clinical trials; conducting clinical trials for others for diagnostic tests and for pharmaceutical preparations; providing temporary use of non-downloadable web-based computer software for data integration, exchange, and analysis; providing biomedical and scientific information in the field of human health and diseases; technology transfer services, namely new product design and development services; scientific research and development services; antibody humanization services, namely antibody engineering in the nature of antibody research and development services; biopharmaceutical product development; biologic assay product development; medical research, namely, preclinical research; clinical research in the in the fields of genetic disorders, infectious diseases and rare diseases; consulting services for others in the design, planning, and implementation of project management of clinical trials; testing and inspection of pharmaceuticals in the nature of pharmacovigilance, namely, monitoring the effects of medical drugs after they have been licensed for use; advisory, consultancy and information services relating to all the aforesaid.

Promoting research in the field of human health and human diseases through the support and coordination of research projects conducted by universities, hospitals, research foundations and businesses; business consultation services in the nature of providing assistance in the field of commercialisation of products and services by identifying routes to market for research; business assistance, management and administration services; advisory, consultancy and information services relating to all the aforesaid; compilation of scientific, medical and clinical information into computer databases; collection of business data in connection with clinical trials for business purposes.

Pharmaceutical treatment diagnostics in the nature of medical and pharmaceutical consultation; medical services; advice on medical information relating to alleviation, diagnosis, prevention and treatment of illnesses and human diseases; advisory, consultancy and information services relating to all the aforesaid.

Charitable fundraising; charitable fundraising collections; organisation of collections in the nature of charitable fundraising; charitable services, namely, provision of funding for research, education, prevention and treatment of illnesses and human diseases; financial grant services, namely, providing grants for research, education, prevention, and treatment of illnesses and human diseases; provision of funding for charities in the nature of philanthropic services concerning monetary donations; charitable foundation services, namely, provision of funding for medical trials; charitable foundation services, namely, provision of funding for educational and research posts; intellectual property venture fund development and formation services for others enabling inventors of new technology to secure appropriate funding for continued technological development; technology transfer services, namely, financial asset management in the nature of managing revenue from partnered or developed intellectual property; advisory, consultancy and information services relating to all the aforesaid.

Downloadable electronic educational and professional publications, namely, newsletters, fact sheets, and brochures about a biomedical and scientific research facility; downloadable electronic educational and professional podcasts and webcasts featuring information about biomedical and scientific research on human health and human diseases.

Providing educational, training and mentoring services concerning the causes, prevention, detection, diagnosis, and treatment of diseases through educational conferences, seminars and written materials disseminated in connection therewith; providing educational conferences, seminars, and webinars in the field of the causes, prevention, detection, diagnosis, and treatment of diseases and dissemination of printed educational materials therewith; providing educational conferences, seminars, and webinars in the field of the causes, prevention, detection, diagnosis, and treatment of diseases and dissemination of online educational materials therewith; publishing including online publishing of journal articles, press releases, white papers and books; advisory, consultancy and information services relating to all the aforesaid.

Printed educational and professional publications, namely, printed newsletters, fact sheets, and brochures about biomedical and scientific research and information about biomedical and scientific research on human health and human diseases.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 18, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 18, 2026 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 28, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 28, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 13, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 13, 2026 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 13, 2026 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 13, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 13, 2026 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 5, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 5, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 5, 2026 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 12, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 12, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 12, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 12, 2026 COAR
REFUSAL PROCESSED BY IB
Oct 18, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 26, 2025 RFCS
REFUSAL PROCESSED BY MPU
Sep 26, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 15, 2025 RFCR
NON-FINAL ACTION WRITTEN
Aug 14, 2025 CNRT
ASSIGNED TO EXAMINER
Aug 13, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 12, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 12, 2025 NWOS
NEW REPRESENTATIVE AT IB RECEIVED
Feb 7, 2025 NREP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 19, 2024 REPR